Nature Medicine | Spoonful of Medicine

Antimalarial armament remains strong, despite lingering concerns over drug resistance

Earlier this month, Indian regulatory authorities granted conditional approval to the country’s first homegrown drug, a malaria-fighting pill that combines a new synthetic form of artemisinin with an older antimalarial compound called piperaquine. If the decision is ratified by the country’s Central Drugs Standard Control Organization, the new drug — developed from start to finish by the New Delhi-based pharmaceutical company Ranbaxy Laboratories — will add to doctors’ armament of artemisinin-based combination therapies (ACTs), the World Health Organization’s medicine of choice for tackling the parasite. Yet with so many options, the question is: which ACT is actually best at treating the infectious disease? 

BACK TO ARTICLE

Tell a Friend

Please ensure that your friend is content to receive an email from us with a link to the article. Select the following link to view our Privacy Policy.

BACK TO ARTICLE